
China Pharma Holdings, Inc.
CPHIAMEXHealthcareDrug Manufacturers - Specialty & Generic
Previous close
$0.98
−$0.08 · -7.55%
CPHI company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
27
Expensive
Momentum
24
Weakening
Sentiment
52
Mixed
Risk resilience
27
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteChina Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Zhilin Li
- Listed since
- Apr 17, 2002
- Employees
- 215
Market position
Day range
Current $0.98
52-week range
Current $0.98
- Open
- $1.031
- Previous close
- $1.06
- Volume
- 275.43K
- 0.06× average
- Average volume
- 4.44M
- Average daily volume
- Market cap
- 39.71M USD
- Beta
- 1.07
- Market reference 1
- 50-day average
- $1.1114
- -11.82% below average
- 200-day average
- $1.0096
- -2.93% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 8.73M USD
- EV / EBITDA
- -5.8×
- Earnings yield
- -61.39%
- Free cash flow yield
- 0.21%
Profitability & efficiency
- Return on equity
- -14.02%
- Return on assets
- -10.28%
- Return on invested capital
- -11.28%
Financial health
- Current ratio
- 0.32×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.14M USD | 4.53M USD | 7.01M USD | 8.1M USD | 9.64M USD |
| Cost of goods sold | 4.28M USD | 6.51M USD | 7.29M USD | 8.6M USD | 9.29M USD |
| Gross profit | −131.95K USD | −1.99M USD | −281.09K USD | −493.92K USD | 349.27K USD |
| Research and development | 280.9K USD | 283.94K USD | 240.08K USD | 185.86K USD | 318.96K USD |
| Selling, general, and administrative | 2.83M USD | 2.31M USD | 2.25M USD | 2.96M USD | 3.15M USD |
| Operating expenses | 2.96M USD | 2.6M USD | 2.47M USD | 3.06M USD | 3.21M USD |
| Interest income | 2K USD | 6.64K USD | 6.6K USD | 10.76K USD | 3.04K USD |
| Interest expense | 102.04K USD | 154.14K USD | 333.6K USD | 434.62K USD | 542K USD |
| Depreciation and amortization | 1.58M USD | 2.62M USD | 2.75M USD | 2.7M USD | 3.09M USD |
| Operating income | −3.09M USD | −4.59M USD | −2.75M USD | −3.55M USD | −2.86M USD |
| Net income | −3.19M USD | −4.74M USD | −3.08M USD | −3.97M USD | −3.4M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -0.04
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
CPHI news
CPHI peers
Continue in GoAI
Research CPHIresearch.disclaimer









